Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Comparative Analysis of Risk Stratification Scores in Atrial Fibrillation

Author(s): Athanasios Samaras, Ioannis Doundoulakis *, Christina Antza, Stefanos Zafeiropoulos, Ioannis Farmakis and Apostolos Tzikas

Volume 27, Issue 10, 2021

Published on: 10 December, 2020

Page: [1298 - 1310] Pages: 13

DOI: 10.2174/1381612826666201210113328

Price: $65

Abstract

Background: Atrial Fibrillation (AF) has become a major global health concern and is associated with an increased risk of poor outcomes. Identifying risk factors in patients with AF can be challenging, given the high burden of comorbidities in these patients. Risk stratification schemes appear to facilitate accurate prediction of outcomes and assist therapeutic management decisions.

Objective: To summarize current evidence on risk stratification scores for patients with AF.

Results: Traditional risk models rely heavily on demographics and comorbidities, while newer tools have been gradually focusing on novel biomarkers and diagnostic imaging to facilitate more personalized risk assessment. Several studies have been conducted to compare existing risk schemes and identify specific patient populations in which the prognostic ability of each scheme excels. However, current guidelines do not appear to encourage the implementation of risk models in clinical practice, as they have not incorporated new ones in their recommendations for the management of patients with AF for almost a decade.

Conclusion: Further work is warranted to analyze new reliable risk stratification schemes and optimally implement them into routine clinical life.

Keywords: Atrial fibrillation, risk stratification, risk score, mortality, stroke, bleeding, review.

« Previous Next »
[1]
Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129(8): 837-47.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005119] [PMID: 24345399]
[2]
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update : A report from the American Heart Association. Circulation 2015; 131(4)
[http://dx.doi.org/10.1161/CIR.0000000000000152]
[3]
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285(18): 2370-5.
[http://dx.doi.org/10.1001/jama.285.18.2370] [PMID: 11343485]
[4]
Morillo CA, Banerjee A, Perel P, Wood D, Jouven X. Atrial fibrillation: the current epidemic. J Geriatr Cardiol 2017; 14(3): 195-203.
[PMID: 28592963]
[5]
Stewart S, Hart CL, Hole DJ, McMurray JJV. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113(5): 359-64.
[http://dx.doi.org/10.1016/S0002-9343(02)01236-6] [PMID: 12401529]
[6]
Thrall G, Lane D, Carroll D, Lip GYH. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006; 119(5): 448.e1-8.e19.
[http://dx.doi.org/10.1016/j.amjmed.2005.10.057] [PMID: 16651058]
[7]
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22(8): 983-8.
[http://dx.doi.org/10.1161/01.STR.22.8.983] [PMID: 1866765]
[8]
Perera KS, Vanassche T, Bosch J, et al. ESUS Global Registry Investigators. Global survey of the frequency of atrial fibrillation-associated stroke: embolic stroke of undetermined source global registry. Stroke 2016; 47(9): 2197-202.
[http://dx.doi.org/10.1161/STROKEAHA.116.013378] [PMID: 27507860]
[9]
Pastori D, Pignatelli P, Angelico F, et al. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. Chest 2015; 147(6): 1644-50.
[http://dx.doi.org/10.1378/chest.14-2414] [PMID: 25429521]
[10]
Violi F, Soliman EZ, Pignatelli P, Pastori D. Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms. J Am Heart Assoc 2016; 5(5)e003347
[http://dx.doi.org/10.1161/JAHA.116.003347] [PMID: 27208001]
[11]
Pokorney SD, Piccini JP, Stevens SR, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF. J Am Heart Assoc 2015; 5(3)e002197
[PMID: 26955859]
[12]
Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38): 2893-962.
[http://dx.doi.org/10.1093/eurheartj/ehw210] [PMID: 27567408]
[13]
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74(1): 104-32.
[http://dx.doi.org/10.1016/j.jacc.2019.01.011] [PMID: 30703431]
[14]
Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther 2014; 8: 789-98.
[http://dx.doi.org/10.2147/DDDT.S45644] [PMID: 24970997]
[15]
Kartas A, Samaras A, Vasdeki D, et al. Flaws in anticoagulation strategies in patients with atrial fibrillation at hospital discharge. J Cardiovasc Pharmacol Ther 2019; 24(3): 225-32.
[http://dx.doi.org/10.1177/1074248418821712] [PMID: 30599759]
[16]
Tzikas A, Holmes DR Jr, Gafoor S, et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. EuroIntervention 2016; 12(1): 103-11.
[http://dx.doi.org/10.4244/EIJV12I1A18] [PMID: 27173870]
[17]
Pastori D, Menichelli D, Gingis R, Pignatelli P, Violi F. Tailored practical management of patients with atrial fibrillation: a risk factor-based approach. Front Cardiovasc Med 2019; 6: 17.https://www.frontiersin.org/article/10.3389/fcvm.2019.00017/full
[18]
Proietti M, Farcomeni A, Romiti GF, et al. Association between clinical risk scores and mortality in atrial fibrillation: Systematic review and network meta-regression of 669,000 patients. Eur J Prev Cardiol 2018; 7(6): 633-44.
[PMID: 30861693]
[19]
Hijazi Z, Oldgren J, Lindbäck J, et al. ARISTOTLE and RE-LY Investigators. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. Eur Heart J 2018; 39(6): 477-85.
[http://dx.doi.org/10.1093/eurheartj/ehx584] [PMID: 29069359]
[20]
Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.
[http://dx.doi.org/10.1056/NEJMoa1107039] [PMID: 21870978]
[21]
Lopes RD, Alexander JH, Al-Khatib SM, et al. ARISTOTLE Investigators Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159(3): 331-9.
[http://dx.doi.org/10.1016/j.ahj.2009.07.035] [PMID: 20211292]
[22]
Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139-51.
[http://dx.doi.org/10.1056/NEJMoa0905561] [PMID: 19717844]
[23]
Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009; 157(5): 805-10.
[http://dx.doi.org/10.1016/j.ahj.2009.02.005] [PMID: 19376304]
[24]
Pallazola VA, Kapoor RK, Kapoor K, McEvoy JW, Blumenthal RS, Gluckman TJ. Anticoagulation risk assessment for patients with non-valvular atrial fibrillation and venous thromboembolism: A clinical review. United Kingdom. Vascular Medicine 2019; 1(2)
[http://dx.doi.org/10.1177/1358863X18819816]
[25]
Fox KAA, Lucas JE, Pieper KS, et al. GARFIELD-AF Investigators Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open 2017; 7(12)e017157
[http://dx.doi.org/10.1136/bmjopen-2017-017157] [PMID: 29273652]
[26]
Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J 2012; 163(1): 13-19.e1.
[http://dx.doi.org/10.1016/j.ahj.2011.09.011] [PMID: 22172431]
[27]
Piccini JP, Fraulo ES, Ansell JE, et al. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J 2011; 162(4): 606-612.e1.
[http://dx.doi.org/10.1016/j.ahj.2011.07.001] [PMID: 21982650]
[28]
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154(13): 1449-57.
[http://dx.doi.org/10.1001/archinte.1994.00420130036007] [PMID: 8018000]
[29]
McBride R. Stroke prevention in atrial fibrillation study: Final results. Circulation 1991; 84(2): 527-39.
[http://dx.doi.org/10.1161/01.CIR.84.2.527] [PMID: 1860198]
[30]
Stroke Prevention in Atrial Fibrillation Investigators Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343(8899): 687-91.
[31]
The stroke prevention in atrial fibrillation III study: rationale, design, and patient features. J Stroke Cerebrovasc Dis 1997; 6(5): 341-53.
[http://dx.doi.org/10.1016/S1052-3057(97)80217-0] [PMID: 17895032]
[32]
Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke 1999; 30(6): 1223-9.
[http://dx.doi.org/10.1161/01.STR.30.6.1223] [PMID: 10356104]
[33]
van Walraven C, Hart RG, Wells GA, et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003; 163(8): 936-43.
[http://dx.doi.org/10.1001/archinte.163.8.936] [PMID: 12719203]
[34]
Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004; 110(16): 2287-92.
[http://dx.doi.org/10.1161/01.CIR.0000145172.55640.93] [PMID: 15477396]
[35]
Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE. ATRIA Study Group.Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008; 51(8): 810-5.
[http://dx.doi.org/10.1016/j.jacc.2007.09.065] [PMID: 18294564]
[36]
Hart RG. Stroke Risk in Atrial Fibrillation Working Group.Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008; 39(6): 1901-10.
[http://dx.doi.org/10.1161/STROKEAHA.107.501825] [PMID: 18420954]
[37]
Lip GYH, Lane D, Van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006; 37(9): 2294-300.
[http://dx.doi.org/10.1161/01.STR.0000236840.00467.84] [PMID: 16888271]
[38]
Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112(12): 1687-91.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.553438] [PMID: 16157766]
[39]
Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines. 8th ition). Chest 2008. Available from:. http://www.ncbi.nlm.nih.gov/pubmed/18574273
[40]
Fuster V, Rydén LE, Cannom DS, et al. European Heart Rhythm Association; Heart Rhythm Society; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation. ACC/AHA/ ESC 2006 guidelines for the management of patients with atrial fibrillation-- executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines J Am Coll Cardiol 2006; 48(4): 854-906..
[http://dx.doi.org/10.1016/j.jacc.2006.07.009] [PMID: 16904574]
[41]
Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003; 290(8): 1049-56.
[http://dx.doi.org/10.1001/jama.290.8.1049] [PMID: 12941677]
[42]
Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137(2): 263-72.
[http://dx.doi.org/10.1378/chest.09-1584] [PMID: 19762550]
[43]
Ntaios G, Lip GYH, Makaritsis K, et al. CHADS2, CHA2S2DS2-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology 2013; 80(11): 1009-17.
[http://dx.doi.org/10.1212/WNL.0b013e318287281b] [PMID: 23408865]
[44]
Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33(12): 1500-10.
[http://dx.doi.org/10.1093/eurheartj/ehr488] [PMID: 22246443]
[45]
Okumura K, Inoue H, Atarashi H, Yamashita T, Tomita H, Origasa H. J-RHYTHM Registry Investigators. Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry. Circ J 2014; 78(7): 1593-9.
[http://dx.doi.org/10.1253/circj.CJ-14-0144] [PMID: 24759791]
[46]
January CT, Wann LS, Alpert JS, et al. ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130(23): 2071-104.
[http://dx.doi.org/10.1161/CIR.0000000000000040] [PMID: 24682348]
[47]
Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc 2013; 2(3)e000250
[http://dx.doi.org/10.1161/JAHA.113.000250] [PMID: 23782923]
[48]
Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131(12): 927-34.
[http://dx.doi.org/10.7326/0003-4819-131-12-199912210-00004] [PMID: 10610643]
[49]
Hijazi Z, Lindbäck J, Alexander JH, et al. ARISTOTLE and STABILITY Investigators The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016; 37(20): 1582-90.
[http://dx.doi.org/10.1093/eurheartj/ehw054] [PMID: 26920728]
[50]
White HD, Held C, Stewart R, et al. STABILITY Investigators Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014; 370(18): 1702-11.
[http://dx.doi.org/10.1056/NEJMoa1315878] [PMID: 24678955]
[51]
White H, Held C, Stewart R, et al. Study design and rationale for the clinical outcomes of the STABILITY Trial (stabilization of atherosclerotic plaque By Initiation of darapLadIb therapy) comparing darapladib versus placebo in patients with coronary heart disease. Am Heart J 2010; 160(4): 655-61.
[http://dx.doi.org/10.1016/j.ahj.2010.07.006] [PMID: 20934559]
[52]
Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151(3): 713-9.
[http://dx.doi.org/10.1016/j.ahj.2005.04.017] [PMID: 16504638]
[53]
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5): 1093-100.
[http://dx.doi.org/10.1378/chest.10-0134] [PMID: 20299623]
[54]
Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur Heart J 2008; 29(9): 1181-9.
[http://dx.doi.org/10.1093/eurheartj/ehn139] [PMID: 18397874]
[55]
Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58(4): 395-401.
[http://dx.doi.org/10.1016/j.jacc.2011.03.031] [PMID: 21757117]
[56]
O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015; 36(46): 3258-64.
[http://dx.doi.org/10.1093/eurheartj/ehv476] [PMID: 26424865]
[57]
Hijazi Z, Oldgren J, Lindbäck J, et al. ARISTOTLE and RE-LY Investigators The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387(10035): 2302-11.
[http://dx.doi.org/10.1016/S0140-6736(16)00741-8] [PMID: 27056738]
[58]
Fanola CL, Giugliano RP, Ruff CT, et al. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. Eur Heart J 2017; 38(12): 888-96.
[http://dx.doi.org/10.1093/eurheartj/ehw565] [PMID: 28064150]
[59]
Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369(22): 2093-104.
[http://dx.doi.org/10.1056/NEJMoa1310907] [PMID: 24251359]
[60]
Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation- Thrombolysis in Myocardial Infa. Am Heart J 2010; 160(4): 635-41.
[http://dx.doi.org/10.1016/j.ahj.2010.06.042]
[61]
Pastori D, Farcomeni A, Poli D, et al. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. Intern Emerg Med 2016; 11(2): 199-204.
[http://dx.doi.org/10.1007/s11739-015-1326-1] [PMID: 26471883]
[62]
Rivera-Caravaca JM, Marín F, Esteve-Pastor MA, et al. Usefulness of the 2MACE score to predicts adverse cardiovascular events in patients with atrial fibrillation. Am J Cardiol 2017; 120(12): 2176-81.
[http://dx.doi.org/10.1016/j.amjcard.2017.09.003] [PMID: 29111209]
[63]
Polovina M, Đikić D, Vlajković A, et al. Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score. Int J Cardiol 2017; 249: 191-7.
[http://dx.doi.org/10.1016/j.ijcard.2017.09.154] [PMID: 28986061]
[64]
Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA 2015; 314(10): 1030-8.
[http://dx.doi.org/10.1001/jama.2015.10725] [PMID: 26318604]
[65]
Gallego P, Roldán V, Torregrosa JM, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2012; 5(2): 312-8.
[http://dx.doi.org/10.1161/CIRCEP.111.967000]
[66]
Diemberger I, Fantecchi E, Reggiani MLB, et al. Atrial fibrillation and prediction of mortality by conventional clinical score systems according to the setting of care. Int J Cardiol 2018; 261: 73-7.
[http://dx.doi.org/10.1016/j.ijcard.2018.03.058] [PMID: 29572083]
[67]
Chao TF, Lin YJ, Tsao HM, et al. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. J Am Coll Cardiol 2011; 58(23): 2380-5.
[http://dx.doi.org/10.1016/j.jacc.2011.08.045] [PMID: 22115643]
[68]
Larsen TB, Lip GYH, Skjøth F, Due KM, Overvad K, Hvilsted Rasmussen L. Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study. Circ Cardiovasc Qual Outcomes 2012; 5(3): 335-42.
[http://dx.doi.org/10.1161/CIRCOUTCOMES.111.964023] [PMID: 22534406]
[69]
Puurunen MK, Kiviniemi T, Schlitt A, et al. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. Thromb Res 2014; 133(4): 560-6.
[http://dx.doi.org/10.1016/j.thromres.2014.01.007] [PMID: 24461143]
[70]
Jacobs V, May HT, Bair TL, et al. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation. Heart Rhythm 2015; 12(4): 681-6.
[http://dx.doi.org/10.1016/j.hrthm.2014.12.034]
[71]
Avgil Tsadok M, Berliner Senderey A, Reges O, et al. Comparison of Stroke Risk Stratification Scores for Atrial Fibrillation. Am J Cardiol 2019; 123(11): 1828-34.
[http://dx.doi.org/10.1016/j.amjcard.2019.02.056] [PMID: 30926148]
[72]
Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GYH. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 2011; 9(1): 39-48.
[http://dx.doi.org/10.1111/j.1538-7836.2010.04085.x] [PMID: 21029359]
[73]
Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124.
[http://dx.doi.org/10.1136/bmj.d124] [PMID: 21282258]
[74]
Poli D, Lip GY, Antonucci E, Grifoni E, Lane D. Stroke risk stratification in a “real-world” elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol 2011; 22(1): 25-30.
[http://dx.doi.org/10.1111/j.1540-8167.2010.01858.x] [PMID: 20653814]
[75]
Lip GYH, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010; 41(12): 2731-8.
[http://dx.doi.org/10.1161/STROKEAHA.110.590257] [PMID: 20966417]
[76]
Aspberg S, Chang Y, Atterman A, Bottai M, Go AS, Singer DE. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J 2016; 37(42): 3203-10.
[http://dx.doi.org/10.1093/eurheartj/ehw077] [PMID: 26941204]
[77]
Zhu W, Fu L, Ding Y, et al. Meta-analysis of ATRIA versus CHA2DS2-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. Int J Cardiol 2017; 227: 436-42.
[http://dx.doi.org/10.1016/j.ijcard.2016.11.015] [PMID: 27839802]
[78]
van den Ham HA, Klungel OH, Singer DE, Leufkens HGM, van Staa TP. Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation: results from a national primary care database. J Am Coll Cardiol 2015; 66(17): 1851-9.
[http://dx.doi.org/10.1016/j.jacc.2015.08.033] [PMID: 26493655]
[79]
Lip GYH, Nielsen PB, Skjøth F, Lane DA, Rasmussen LH, Larsen TB. The value of the European Society of Cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: A Nationwide Co. Chest 2014.
[http://dx.doi.org/10.1378/chest.14-0533]
[80]
Abumuaileq RRY, Abu-Assi E, López-López A, et al. Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord 2015; 15: 156.
[http://dx.doi.org/10.1186/s12872-015-0149-3] [PMID: 26584938]
[81]
Chao TF, Liu CJ, Wang KL, et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in ‘low-risk’ Asian patients with atrial fibrillation. J Am Coll Cardiol 2014; 64(16): 1658-65.
[http://dx.doi.org/10.1016/j.jacc.2014.06.1203] [PMID: 25323252]
[82]
Oldgren J, Hijazi Z, Lindbäck J, et al. RE-LY and ARISTOTLE Investigators Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation. Circulation 2016; 134(22): 1697-707.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.022802] [PMID: 27569438]
[83]
Berg DD, Ruff CT, Jarolim P, et al. Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48. Circulation 2019; 139(6): 760-71.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.038312] [PMID: 30586727]
[84]
Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, et al. Long-term stroke risk prediction in patients with atrial fibrillation: Comparison of the ABC-stroke and CHA2DS2-VASc scores. J Am Heart Assoc 2017; 6(7)e006490
[http://dx.doi.org/10.1161/JAHA.117.006490] [PMID: 28729407]
[85]
Olesen JB, Lip GYH, Hansen PR, et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost 2011; 9(8): 1460-7.
[http://dx.doi.org/10.1111/j.1538-7836.2011.04378.x] [PMID: 21624047]
[86]
Amadeus I, Bousser MG, Bouthier J, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008; 371(9609): 315-21. Available from:. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=med5&AN=18294998
[87]
Apostolakis S, Lane DA, Guo Y, Buller H, Lip GYH. Performance of the HEMORR 2HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: The AMADEUS (Evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial. J Am Coll Cardiol 2012; 60(9): 861-7.
[http://dx.doi.org/10.1016/j.jacc.2012.06.019]
[88]
Roldán V, Marín F, Fernández H, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a “real-world” population with atrial fibrillation receiving anticoagulant therapy. Chest 2013; 143(1): 179-84.
[http://dx.doi.org/10.1378/chest.12-0608] [PMID: 22722228]
[89]
Caldeira D, Costa J, Fernandes RM, Pinto FJ, Ferreira JJ. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol 2014; 40(3): 277-84.
[http://dx.doi.org/10.1007/s10840-014-9930-y] [PMID: 25012972]
[90]
Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis. Clin Cardiol 2015; 38(9): 555-61.
[http://dx.doi.org/10.1002/clc.22435] [PMID: 26418409]
[91]
Senoo K, Proietti M, Lane DA, Lip GYH. Evaluation of the HAS-BLED, ATRIA, and ORBIT bleeding risk scores in patients with atrial fibrillation taking warfarin. Am J Med 2016; 129(6): 600-7.
[http://dx.doi.org/10.1016/j.amjmed.2015.10.001] [PMID: 26482233]
[92]
Proietti M, Senoo K, Lane DA, Lip GYH. Major bleeding in patients with non-valvular atrial fibrillation: impact of time in therapeutic range on contemporary bleeding risk scores. Sci Rep 2016; 6: 24376.
[http://dx.doi.org/10.1038/srep24376] [PMID: 27067661]
[93]
Fauchier L, Chaize G, Gaudin AF, Vainchtock A, Rushton-Smith SK, Cotté FE. Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation. A French nationwide cross-sectional study. Int J Cardiol 2016; 217: 85-91.
[http://dx.doi.org/10.1016/j.ijcard.2016.04.173] [PMID: 27179213]
[94]
Proietti M, Hijazi Z, Andersson U, et al. RE-LY Investigators. Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial. J Intern Med 2018; 283(3): 282-92.
[http://dx.doi.org/10.1111/joim.12702] [PMID: 29044861]
[95]
Wang C, Yu Y, Zhu W, Yu J, Lip GYH, Hong K. Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. Oncotarget 2017; 8(65): 109703-11.
[http://dx.doi.org/10.18632/oncotarget.19858] [PMID: 29312640]
[96]
Proietti M, Rivera-Caravaca JM, Esteve-Pastor MA, Romiti GF, Marin F, Lip GYH. Predicting bleeding events in anticoagulated patients with atrial fibrillation: A comparison between the HAS-BLED and GARFIELD-AF bleeding scores. J Am Heart Assoc 2018; 7(18)e009766
[http://dx.doi.org/10.1161/JAHA.118.009766] [PMID: 30371183]
[97]
Pérez Cabeza AI, Bravo Marques R, Chinchurreta Capote PA, et al. TIMI-AF score and cardiovascular events in vitamin K antagonists-naïve outpatients with atrial fibrillation. Clin Cardiol 2018; 41(9): 1252-8.
[http://dx.doi.org/10.1002/clc.23035] [PMID: 30062699]
[98]
Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA, et al. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED. Am Heart J 2018; 197: 27-34.
[http://dx.doi.org/10.1016/j.ahj.2017.11.004] [PMID: 29447781]
[99]
Pastori D, Rivera-Caravaca JM, Esteve-Pastor MA, et al. Comparison of the 2MACE and TIMI-AF scores for composite clinical outcomes in anticoagulated atrial fibrillation patients. Circ J 2018; 82(5): 1286-92.
[http://dx.doi.org/10.1253/circj.CJ-17-1318] [PMID: 29553090]
[100]
John Camm A, Lip GYH, De Caterina R, et al. Focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012.
[101]
Chao TF, Lip GYH, Liu CJ, et al. Relationship of aging and incident comorbidities to stroke risk in patients with atrial fibrillation. J Am Coll Cardiol 2018; 71(2): 122-32.
[http://dx.doi.org/10.1016/j.jacc.2017.10.085] [PMID: 29325634]
[102]
Kirchhof P. The future of atrial fibrillation management: integrated care and stratified therapy. Lancet 2017; 390(10105): 1873-87.
[http://dx.doi.org/10.1016/S0140-6736(17)31072-3] [PMID: 28460828]
[103]
Kotecha D, Breithardt G, Camm AJ, et al. Integrating new approaches to atrial fibrillation management: The 6th AFNET/EHRA Consensus Conference Europace 2018.
[104]
Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14(11): 627-8.
[http://dx.doi.org/10.1038/nrcardio.2017.153] [PMID: 28960189]
[105]
Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. Am J Med 2018; 131(11): 1359-1366.e6.
[http://dx.doi.org/10.1016/j.amjmed.2018.06.012] [PMID: 30153428]
[106]
Gallagher C, Elliott AD, Wong CX, et al. Integrated care in atrial fibrillation: a systematic review and meta-analysis. Heart 2017; 103(24): 1947-53.
[http://dx.doi.org/10.1136/heartjnl-2016-310952] [PMID: 28490616]

Rights & Permissions Print Cite
Article Metrics
91
1
© 2024 Bentham Science Publishers | Privacy Policy